Folate for Better Rheumatoid Results

A Canadian review found that, based on evidence from double-blind randomized, placebo-controlled clinical trials, folate supplementation helped reduce the side effects of the drug, methotrexate (MTX), in this case used for treating severe rheumatoid arthritis (RA).

Methotrexate is a powerful drug with the potential to cause serious side effects, including damage to the stomach and intestinal lining, skin reactions, liver damage and cancer. The reviewers included only those studies that were well-structured and used low-dose levels of folic acid. They ended up choosing six trials with 624 patients that met their criteria.

Patients supplemented with any form of folate, either folic acid or folinic (reduced folic acid) while receiving MTX therapy for RA, a 26 percent relative reduction of risk was noted for stomach-related side effects, including abdominal pain, vomiting, or nausea.

Folates have long been considered a must for preventing spinal birth defects and promoting healthy blood pressure, but the fact that this common nutrient alleviates damaging side effects of MTX may come as a surprise to those undergoing therapy with the drug. This review shows that studies using small amounts allowed individuals to stay with their therapeutic protocols, and do so safely. Because folates make MTX more tolerable for patients with RA means that people are less likely to drop out of their regimen, and illustrates how important common nutrients are in the diet, in ways we might not expect.

Abstract:

Shea B, Swinden MV, Ghogomu ET, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. J Rheumatol. 2014 Jun;41(6):1049-60.

BACKGROUND: Methotrexate (MTX) is a disease modifying antirheumatic drug (DMARD) used as a first line agent for treating rheumatoid arthritis (RA). Pharmacologically, it is classified as an antimetabolite due to its antagonistic effect on folic acid metabolism. Many patients treated with MTX experience mucosal, gastrointestinal, hepatic or haematologic side effects. Supplementation with folic or folinic acid during treatment with MTX may ameliorate these side effects.

OBJECTIVES: To identify trials of supplementation with folic acid or folinic acid during MTX therapy for rheumatoid arthritis and to assess the benefits and harms of folic acid and folinic acid (a) in reducing the mucosal, gastrointestinal (GI), hepatic and haematologic side effects of MTX, and (b) whether or not folic or folinic acid supplementation has any effect on MTX benefit.

SEARCH METHODS: We originally performed MEDLINE searches, from January 1966 to June 1999. During the update of this review, we searched additional databases and used a sensitive search strategy designed to retrieve all trials on folic acid or folinic acid for rheumatoid arthritis from 1999 up to 2 March 2012.

SELECTION CRITERIA: We selected all double-blind, randomised, placebo-controlled clinical trials (RCTs) in which adult patients with rheumatoid arthritis were treated with MTX (at a dose equal to or less than 25 mg/week) concurrently with folate supplementation. In this update of the review we only included trials using 'low dose' folic or folinic acid (a starting dose of ≤ 7 mg weekly).

DATA COLLECTION AND ANALYSIS: Data were extracted from the trials, and the trials were independently assessed for risk of bias using a predetermined set of criteria.

MAIN RESULTS: Six trials with 624 patients were eligible for inclusion. Most studies had low or unclear risk of bias for key domains. The quality of the evidence was rated as 'moderate' for each outcome as assessed by GRADE, with the exception of haematologic side effects which were rated as 'low'. There was no significant heterogeneity between trials, including where folic acid and folinic acid studies were pooled.For patients supplemented with any form of exogenous folate (either folic or folinic acid) whilst on MTX therapy for rheumatoid arthritis, a 26% relative (9% absolute) risk reduction was seen for the incidence of GI side effects such as nausea, vomiting or abdominal pain (RR 0.74, 95% CI 0.59 to 0.92; P = 0.008). Folic and folinic acid also appear to be protective against abnormal serum transaminase elevation caused by MTX, with a 76.9% relative (16% absolute) risk reduction (RR 0.23, 95% CI 0.15 to 0.34; P < 0.00001), as well as reducing patient withdrawal from MTX for any reason (60.8% relative (15.2% absolute) risk reduction, RR 0.39, 95% CI 0.28 to 0.53; P < 0.00001).We analysed the effect of folic or folinic acid on the incidence of stomatitis / mouth sores, and whilst showing a trend towards reduction in risk, the results were not statistically significant (RR 0.72, 95% CI 0.49 to 1.06)It was not possible to draw meaningful conclusions on the effect of folic or folinic acid on haematologic side effects of methotrexate due to small numbers of events and poor reporting of this outcome in included trials.It does not appear that supplementation with either folic or folinic acid has a statistically significant effect on the efficacy of MTX in treating RA (as measured by RA disease activity parameters such as tender and swollen joint counts, or physician's global assessment scores).

AUTHORS' CONCLUSIONS: The results support a protective effect of supplementation with either folic or folinic acid for patients with rheumatoid arthritis during treatment with MTX.There was a significant reduction shown in the incidence of GI side effects, hepatic dysfunction (asmeasured by elevated serum transaminase levels) as well as a significant reduction in discontinuation of MTX treatment for any reason. A trend towards a reduction in stomatitis was demonstrated however this did not reach statistical significance.This updated review with its focus on lower doses of folic acid and folinic acid and updated assessment of risk of bias aimed to give a more precise and more clinically relevant estimate of the benefit of folate supplementation for patients with rheumatoid arthritis receiving methotrexate.

Our website uses cookies to track website usage and preferences. You can read more about cookies here or by visiting our privacy policy. I Understand

Stay Connected

[Connect on Social Media and sign up for my E-Newsletter]

Terry is happy to provide his opinion on diet and nutrition, supplements and lifestyle choices. This information is for educational purposes only. It is not meant to replace the advice of your physician and is not to be considered medical advice, diagnosis or treatment. Should you have any concerns please contact your physician directly.

Choose Your Topics of Interest

[Choose from topics below to personalize articles fed to your home page]

Bones, Joints & Tendons
Cancer
Children's Health
Upper-Respiratory Tract Health
Diabetes & Neuropathy
Digestion & Gut Health
Eye, Hair, Nails & Skin
Energy & Fatigue
Heart Disease & Stroke
High Blood Pressure
Cholesterol
Sleep Disturbances
Brain & Cognitive
Menopause
Men's Health
Pain Relief
Immunity
Pet Health
Mental Health/Mood & Stress
Thyroid & Adrenal
Women's Health
Sexual Health
Weight Loss